Agios Pharmaceuticals announced that its oral pyruvate kinase activator, tebapivat, did not show sufficient differentiation in Phase 2 trials to warrant continued development for sickle cell disease. While the drug demonstrated hemoglobin response rates consistent with its class, the company will not advance it further in this indication, shifting focus to its foundational PK activator, mitapivat.
Agios Pharmaceuticals has decided to discontinue the development of tebapivat for sickle cell disease following Phase 2 trial results. While the drug showed some efficacy in improving hemoglobin levels, it did not demonstrate a differentiated profile compared to other PK activators, including the company's own mitapivat. This decision is a negative for AGIO as it removes a potential future revenue stream and narrows its pipeline in sickle cell disease. However, the company's primary focus remains on mitapivat, which is under FDA Priority Review for sickle cell disease with a PDUFA goal date of November 1, 2026. The short-term impact on AGIO could be a slight dip due to the pipeline reduction, but the long-term outlook will largely depend on the success and market penetration of mitapivat.